Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Merck Initiates Phase 3 Clinical trial for PCSK9 Inhibitor MK-0616
Latest Hotspot
4 min read
Merck Initiates Phase 3 Clinical trial for PCSK9 Inhibitor MK-0616
29 August 2023
Merck has today made public the launch of the company's Phase 3 clinical trials, labeled as CORALreef, for MK-0616, a potential oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.
Read →
Easily Obtain Gene Sequences by Using Gene Names in The Patsnap Bio Database
Bio Sequence
3 min read
Easily Obtain Gene Sequences by Using Gene Names in The Patsnap Bio Database
29 August 2023
Acquiring the sequence of a gene founded on its title is feasible and this article introduces one uncomplicated and swift technique that is consistently utilized.
Read →
How does AstraZeneca's PARP inhibitor differentiate?
Valuable Targets
10 min read
How does AstraZeneca's PARP inhibitor differentiate?
28 August 2023
PARP inhibitors had once brought about a "decade breakthrough" for ovarian cancer, and in search for new areas of business growth, AZ is primarily seeking the approval for the use of olaparib in metastatic prostate cancer.
Read →
Can Arvinas lead the treatment of neurodegenerative diseases?
Advanced Tech.
8 min read
Can Arvinas lead the treatment of neurodegenerative diseases?
25 August 2023
Arvinas is currently conducting preclinical studies on protein degradation for neurodegenerative diseases.
Read →
The world's first Maternal Vaccine! Analysis of Pfizer's RSV Vaccine
Drug Insights
3 min read
The world's first Maternal Vaccine! Analysis of Pfizer's RSV Vaccine
25 August 2023
This is the first and only RSV vaccine for pregnant women, marking an important milestone for public health.
Read →
Sales fall short of expectations, how can KRAS G12C be differentiated in R&D?
Valuable Targets
10 min read
Sales fall short of expectations, how can KRAS G12C be differentiated in R&D?
25 August 2023
With KRAS, a previously considered untouchable target, being cracked open, the KRAS G12C inhibitors of Amgen and Mirati are now on the market. The question is, how can we further optimize treatment outcomes for patients?
Read →
Variation Report — A Valuable Tool for Investigating Sequence Mutations within Drug Development
Bio Sequence
3 min read
Variation Report — A Valuable Tool for Investigating Sequence Mutations within Drug Development
24 August 2023
Adeno-associated virus (AAV) is reckoned as one of the most propitious vectors for gene research and therapy. It is recommended to use the Patsnap Bio sequence database to extract sequences analogous to definite AAV sequences and examine new AAV data from sources accessible to the public, thereby providing a catalyst for advanced AAV research.
Read →
Analysis of Moderna's Cancer Vaccine Pipeline
R&D Pipeline
4 min read
Analysis of Moderna's Cancer Vaccine Pipeline
23 August 2023
Merck exercised its option to co-develop and commercialize mRNA-4157/V940 with Moderna for adjuvant treatment in high-risk melanoma patients.
Read →
Similar Sequence Search for Adeno-associated virus (AAV)
Bio Sequence
3 min read
Similar Sequence Search for Adeno-associated virus (AAV)
23 August 2023
Adeno-associated virus (AAV) is reckoned as one of the most propitious vectors for gene research and therapy. It is recommended to use the Patsnap Bio sequence database to extract sequences analogous to definite AAV sequences and examine new AAV data from sources accessible to the public, thereby providing a catalyst for advanced AAV research.
Read →
Synapse: Empowering Pharmaceutical Innovation with Comprehensive Drug Intelligence
Feature Updates
6 min read
Synapse: Empowering Pharmaceutical Innovation with Comprehensive Drug Intelligence
23 August 2023
Synapse is a free drug intelligence database that streamlines research and enhances decision-making for pharmaceutical professionals. With extensive coverage of drugs, targets, and diseases, it provides valuable insights in emerging technology trends and competitive landscapes. Synapse supports partnership and investment decisions with detailed drug pipeline and investment history information.
Read →
Zoledronic Acid holds the key in Fighting Aging-Related Diseases
Advanced Tech.
6 min read
Zoledronic Acid holds the key in Fighting Aging-Related Diseases
22 August 2023
A recent study published in journal Aging has shed light on the potential anti-aging effects of zoledronic acid, a commonly prescribed bisphosphonate.
Read →